First- and second-line drug resistance patterns among previously treated tuberculosis patients in India

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 2, 2010, Pages 243-246

  Paramasivan, C N ^a   Rehman, F ^b   Wares, F ^c   Sundar Mohan, N ^b   Sundar, S ^b   Devi, S ^b   Narayanan, P R ^b  

^a FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^b INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Drug resistance; India; Previously treated tuberculosis

Indexed keywords

ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN;

ARTICLE; BACTERIUM ISOLATE; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; HEALTH CARE QUALITY; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77049088298     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. World Health Organization. Framework for effective tuberculosis control. WHO/TB/94.179. Geneva, Switzerland: WHO, 1994.
2. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
3. World Health Organization. Anti-tuberculosis drug resistance in the world. Fourth global report. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
4. World Health Organization. Report of the meeting of the WHO Global Task Force on XDR-TB. Geneva, Switzerland, 9-10 October 2006. WHO/HTM/TB/2007.375. Geneva, Switzerland: WHO, 2007.
5. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
6. Sulochana S, Rahaman F, Paramasivan C N. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J Chemother 2005; 17: 169-173.
7. Global Alliance for TB Drug Development. Pathway to patients: charting the dynamics of the global TB drug market. New York, NY, USA: Global Alliance for TB Drug Development, 2007.
8. Leimane V, Riekstina V, Holtz T H, et al. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326.
9. Jassal M, Bishai W R. Extensively drug-resistant tuberculosis. Lancet Infect Dis 2009; 9: 19-30.
10. Mlambo C K, Warren R M, Poswa X, Victor T C, Duse A G, Marais E. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis 2008; 12: 99-104.
11. Sisodia R S, Wares F, Sahu S, Chauhan L S, Zignol M. Source of re-treatment cases under the Revised National TB Control Programme in Rajasthan, India, 2003. Int J Tuberc Lung Dis 2006; 10: 1373-1379.
12. Wang J Y, Hsueh P R, Jan I S, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61: 903-908.
13. Agrawal D, Udwadia Z F, Rodriguez C, Mehta A. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis 2009; 13: 79-83.
14. Central TB Division, Directorate General of Health Services, Ministry of Health & Family Welfare. RNTCP Q1 2009 performance report. New Delhi, India: CTD, 2009.